281 related articles for article (PubMed ID: 2509910)
1. Effect of deprenyl on the progression of disability in early Parkinson's disease.
Parkinson Study Group
N Engl J Med; 1989 Nov; 321(20):1364-71. PubMed ID: 2509910
[TBL] [Abstract][Full Text] [Related]
2. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
Shoulson I
Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
[TBL] [Abstract][Full Text] [Related]
3. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.
Parkinson Study Group
N Engl J Med; 1993 Jan; 328(3):176-83. PubMed ID: 8417384
[TBL] [Abstract][Full Text] [Related]
4. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Parkinson Study Group.
Shults CW
Acta Neurol Scand Suppl; 1993; 146():36-42. PubMed ID: 8333252
[TBL] [Abstract][Full Text] [Related]
5. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group.
Shoulson I
Acta Neurol Scand Suppl; 1989; 126():171-5. PubMed ID: 2515723
[TBL] [Abstract][Full Text] [Related]
6. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1989 Oct; 46(10):1052-60. PubMed ID: 2508608
[TBL] [Abstract][Full Text] [Related]
7. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
Rinne UK
J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
[TBL] [Abstract][Full Text] [Related]
8. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
Presthus J; Hajba A
Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
[TBL] [Abstract][Full Text] [Related]
9. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Tetrud JW; Langston JW
Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group.
Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875
[TBL] [Abstract][Full Text] [Related]
11. Deprenyl (selegiline) in the treatment of Parkinson's disease.
Rinne UK
Acta Neurol Scand Suppl; 1983; 95():107-11. PubMed ID: 6428141
[TBL] [Abstract][Full Text] [Related]
12. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Tetrud JW; Langston JW
J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
Csanda E; Tárczy M
Acta Neurol Scand Suppl; 1983; 95():117-22. PubMed ID: 6428143
[TBL] [Abstract][Full Text] [Related]
14. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
Golbe LI; Duvoisin RC
J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
[TBL] [Abstract][Full Text] [Related]
15. L-deprenyl in the treatment of Parkinson's disease.
Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
[TBL] [Abstract][Full Text] [Related]
16. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.
Kieburtz K; McDermott M; Como P; Growdon J; Brady J; Carter J; Huber S; Kanigan B; Landow E; Rudolph A
Neurology; 1994 Sep; 44(9):1756-9. PubMed ID: 7936311
[TBL] [Abstract][Full Text] [Related]
17. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group.
McDermott MP; Jankovic J; Carter J; Fahn S; Gauthier S; Goetz CG; Golbe LI; Koller W; Lang AE; Olanow CW
Arch Neurol; 1995 Jun; 52(6):565-70. PubMed ID: 7763203
[TBL] [Abstract][Full Text] [Related]
18. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
[TBL] [Abstract][Full Text] [Related]
19. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
Przuntek H; Kuhn W
J Neural Transm Suppl; 1987; 25():97-104. PubMed ID: 3123607
[TBL] [Abstract][Full Text] [Related]
20. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
Presthus J; Berstad J; Lien K
Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
